Drug Shortage Report for TEVA-RIZATRIPTAN ODT

Last updated on 2023-04-28 History
Report ID 169983
Drug Identification Number 02396661
Brand name TEVA-RIZATRIPTAN ODT
Common or Proper name TEVA-RIZATRIPTAN OD
Company Name TEVA CANADA LIMITED
Market Status MARKETED
Active Ingredient(s) RIZATRIPTAN
Strength(s) 5MG
Dosage form(s) TABLET (ORALLY DISINTEGRATING)
Route of administration ORAL ORAL
Packaging size 6
ATC code N02CC
ATC description ANTIMIGRAINE PREPARATIONS
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2022-09-22
Estimated end date 2023-03-10
Actual end date 2023-04-27
Shortage status Resolved
Updated date 2023-04-28
Company comments
Health Canada comments
Tier 3 Status No
Contact Address 30 NOVOPHARM COURT
TORONTO, ONTARIO
CANADA M1B 2K9
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v25 2023-04-28 English Compare
v24 2023-04-27 French Compare
v23 2023-04-27 English Compare
v22 2023-02-02 French Compare
v21 2023-02-02 English Compare
v20 2023-01-19 French Compare
v19 2023-01-19 English Compare
v18 2022-12-22 French Compare
v17 2022-12-22 English Compare
v16 2022-12-15 French Compare
v15 2022-12-15 English Compare
v14 2022-12-15 English Compare
v13 2022-12-08 French Compare
v12 2022-12-08 English Compare
v11 2022-12-01 French Compare
v10 2022-12-01 English Compare
v9 2022-11-14 French Compare
v8 2022-11-14 English Compare
v7 2022-10-17 French Compare
v6 2022-10-17 English Compare

Showing 1 to 20 of 25